Zhan Dechao, Chen Zihong, Yang Donghong, Wen Jiyu, Liu Wanwan
Cancer Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, Guangdong, China.
Emerg Med Int. 2022 Aug 11;2022:6293816. doi: 10.1155/2022/6293816. eCollection 2022.
To explore the clinical efficacy and safety of apatinib combined with paclitaxel in the first-line treatment of locally advanced nasopharyngeal carcinoma.
From March 2016 to June 2018, 114 patients with locally advanced nasopharyngeal carcinoma who received first-line treatment in our hospital were selected as the patient group, and those who received apatinib combined with paclitaxel concurrent radiotherapy and chemotherapy were selected as the research group ( = 54), while those who received paclitaxel concurrent radiotherapy and chemotherapy were selected as the control group ( = 60). Sixty healthy individuals in our hospital were recruited in the same period as the healthy group. The clinical effective rate, adverse reactions, 2-year overall survival rate (OS), 2-year progression-free survival rate (PFS), and quality of life were compared between the two groups, and the expression of miR-655 in the serum of each group was tested by RT-qPCR.
The total clinical effective rate of the research group was higher than that of the control group, and the 2-year OS and PFS of the research group were also higher than those of the control group ( < 0.05). Both groups of patients could tolerate the treatment, but the incidence of hypertension and proteinuria in the research group was higher than that in the control group ( < 0.05). The expression of miR-655 in the serum of patients was lower than that of the healthy group ( < 0.05). After treatment, miR-655 in serum increased in both the groups and miR-655 in the research group was higher than that in the control group ( < 0.05). The 2-year survival rate of OS and PFS in patients with low expression of miR-655 was significantly lower than that in patients with high expression of miR-655 ( < 0.05).
Apatinib combined with paclitaxel concurrent radiotherapy and chemotherapy is effective and well-tolerated in the treatment of locally advanced nasopharyngeal carcinoma, which improves the quality of life of patients and can be popularized in clinical practice. In addition, the increase of miR-655 may be a target for treating nasopharyngeal carcinoma.
探讨阿帕替尼联合紫杉醇一线治疗局部晚期鼻咽癌的临床疗效及安全性。
选取2016年3月至2018年6月在我院接受一线治疗的114例局部晚期鼻咽癌患者作为患者组，其中接受阿帕替尼联合紫杉醇同步放化疗的患者作为研究组（n = 54），接受紫杉醇同步放化疗的患者作为对照组（n = 60）。同期选取我院60例健康个体作为健康组。比较两组的临床有效率、不良反应、2年总生存率（OS）、2年无进展生存率（PFS）及生活质量，并采用RT-qPCR检测各组血清中miR-655的表达。
研究组的总临床有效率高于对照组，研究组的2年OS和PFS也高于对照组（P < 0.05）。两组患者均能耐受治疗，但研究组高血压和蛋白尿的发生率高于对照组（P < 0.05）。患者血清中miR-655的表达低于健康组（P < 0.05）。治疗后，两组血清中miR-655均升高，且研究组高于对照组（P < 0.05）。miR-655低表达患者的2年OS和PFS生存率显著低于miR-655高表达患者（P < 0.05）。
阿帕替尼联合紫杉醇同步放化疗治疗局部晚期鼻咽癌有效且耐受性良好，可提高患者生活质量，值得临床推广。此外，miR-655的升高可能是治疗鼻咽癌的一个靶点。
